GlassScriptPhysician profile
Scott A Ross
NPI 1841290129
$3,303.41
in general payments reported to CMS, 2019-2025
29 companies · $968 in 2025
The $968 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $77.97 · 2021: $147 · 2022: $343 · 2023: $1,019 · 2024: $748 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,735.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $458.78 | 2023-2025 | Vraylar |
| Novo Nordisk INC | $394.57 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $305.96 | 2023 | Spravato |
| Otsuka America Pharmaceutical, INC. | $289.83 | 2023-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $280.24 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $157.94 | 2023-2024 | Cobenfy, Eliquis |
| Boston Scientific Corporation | $140.10 | 2025 | Wavewriter Alpha Prime 16 |
| Astrazeneca Pharmaceuticals LP | $130.44 | 2021-2025 | Farxiga, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $127.07 | 2020-2025 | Trintellix |
| Axsome Therapeutics, INC. | $125.00 | 2023 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $124.32 | 2023 | Austedo Xr |
| Glaxosmithkline, LLC. | $112.74 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Vanda Pharmaceuticals INC. | $103.55 | 2024 | Fanapt |
| Exact Sciences Corporation | $91.88 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $66.40 | 2021-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $54.52 | 2025 | Atricure Cryoice Cryoablation System (Cryo2) |
| Genzyme Corporation | $45.09 | 2020 | |
| Abbott Laboratories | $42.63 | 2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $42.63 | 2025 | Zepbound, Mounjaro |
| Regeneron Healthcare Solutions, INC. | $34.61 | 2024 | Dupixent |
| Daiichi Sankyo INC. | $24.29 | 2024 | Injectafer |
| Eisai INC. | $24.19 | 2021 | |
| Tactile Systems Technology INC | $23.55 | 2025 | Nimbl, Flexitouch Plus |
| Xeris Pharmaceuticals, INC. | $21.24 | 2025 | Gvoke Hypopen |
| Corcept Therapeutics | $19.36 | 2025 | Korlym |
| Currax Pharmaceuticals LLC | $17.82 | 2025 | Contrave |
| Amgen INC. | $16.76 | 2025 | Repatha |
| Astellas Pharma US INC | $15.90 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.